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Synthesis and biological evaluation of novel 1,3,4-thiadiazole 
derivatives as possible anticancer agents
The synthesis of new N-(5-substituted-1,3,4-thiadiazol-2-yl)-
-2-[(5-(substituted amino)-1,3,4-thiadiazol-2-yl)thio]acet-
amide derivatives and investigation of their anticancer acti-
vities were the aims of this work. All the new compounds’ 
structures were elucidated by elemental analyses, IR, 1H 
NMR, 13C NMR and MS spectral data. Anticancer activity 
studies of the compounds were evaluated against MCF-7 
and A549 tumor cell lines. In addition, with the purpose of 
determining the selectivity of cytotoxic activities, the most 
active compound was screened against a noncancer NIH3T3 
cell line (mouse embryonic fibroblast cells). Among the tested 
compounds, compound 4y (N-(5-ethyl-1,3,4-thiadiazol-2-yl)-
-2-((5-(p-tolylamino)-1,3,4-thiadiazol-2-yl)thio)acetamide), 
showed promising cytotoxic activity against MCF7 cancer 
cell with an IC50 value of 0.084 ± 0.020 mmol L–1 and against 
A549 cancer cell with IC50 value of 0.034 ± 0.008 mmol L–1, 
compared with cisplatin. The aromatase inhibitory activity 
was evaluated for compound 4y on MCF-7 cell line showing 
promising activity with IC50 of 0.062 ± 0.004 mmol L–1.
Keywords: 1,3,4-thiadiazole, anticancer activity, aromatase 
inhibitory activity, MTT assay
Cancer remains a major cause of death worldwide despite multiple approaches used 
in prevention and therapy. After lung cancer, breast cancer is the second leading cause of 
cancer death among women. About one million women in the world are diagnosed with 
breast cancer every year. Moreover, according to World Conference on Breast Cancer, 
around 400,000 women die from this disease each year (1, 2).
The investigations for breast cancer suggest that many tumors occur and develop 
through estrogen-dependent mechanisms (3). Accordingly, it can be assumed that estro-
gen deprivation may prevent the formation of these cancers or may result in the regression 
of occurred tumors. The target of this suppression is the inhibition of the aromatase en-
zyme, responsible for the cyclization and structuring of estrogen (4). 
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Aromatase is a very promising target for the endocrine treatment of estrogen-depend-
ent diseases. In this sense, attention has been focused on the discovery of aromatase in hi-
bitors able to control the progression of hormone-sensitive breast cancer in women, and 
decrease the circulating levels of estrogens (5, 6). According to their chronological order of 
clinical development, these inhibitors can be divided into three classes. The third-generation 
aromatase inhibitors (non-steroid aromatase inhibitors) are used as first-line therapy for the 
treatment of breast cancer in both early and advanced tumors as shown in Fig. 1. They are 
more selective and/or potent compared with first- and second-generation agents (7).
The strongest interaction with aromatase is a coordinative bond between the lone 
electron pair of an aromatic heterocyclic nitrogen atom and the heme iron of the enzyme 
(8). Compounds containing heterocycles and more than one nitrogen also exert inhibitory 
activity towards aromatase (9).
Thiadiazole has been studied extensively for more than one hundred years due to its 
outstanding therapeutic applications. Thiadiazole is a 5-membered planar aromatic motif 
comprising a sulfur atom, which improves the liposolubility of thiadiazole derivatives and 
hence their pharmacokinetics (10). From the literature survey, it was noticed that 1,3,4-thia-
diazole derivatives possess many pharmacological activities, such as antiviral (11), anti-
bacterial (12), antileishmanial (13), antitubercular (14), antimycobacterial (15), anticonvul-
sant (16) and analgesic activity (17). Different mechanisms of the antitumor activity of 
1,3,4-thiadiazoles have been reported, including specific inhibition of epidermal growth 
factor receptor (EGFR) kinase (18), carbonic anhydrase (19), phosphodiesterase-7 (PDE7) 
(20), tyrosine kinase (21) and aromatase (22). In the view of the aforesaid, we designed and 
synthesized two thiadiazole-ring systems.
EXPERIMENTAL
Materials and methods
All of the chemicals used in the study were purchased either from Merck (Merck 
KGaA, Germany) or Sigma-Aldrich (USA) and used without further purification.
The purity of the compounds was checked by classical TLC on silica gel 60 F254 (Merck).
Melting points of the synthesized compounds were determined using an MP90 series 
automatic melting point determination system (Mettler-Toledo, USA) and were presented 
as uncorrected.
1H and 13C NMR spectra were recorded in DMSO-d6 by a Bruker digital FT-NMR 



















Fig. 1. The third generation of aromatase inhibitors.
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the NMR spectra were designated as follows: s – singlet, d – doublet, t – triplet, m – multi-
plet; coupling constants (J) were reported in hertz). M+1 peaks were determined by the 
Shimadzu LC/MS ITTOF system (Shimadzu, Japan). 
Syntheses
General procedure for N-substituted-hydrazinecarbothioamides (1a-j). – A mixture of 
suitable isothiocyanate derivative (0.02 mol) and hydrazine hydrate (0.04 mol) was stirred 
in ethanol (99 %) (30 mL) for 4 h at 80 °C. After completion of the reaction, the precipitated 
product was filtered and washed with cold-ethanol. 
General procedure for 5-(substituted-amino)-1,3,4-thiadiazole-2-thiols (2a-j). – Carbon 
disulfide (0.019 mol) was added into a solution of compound 1a-j (0.018 mol) in EtOH (99 
%) in the presence of sodium hydroxide (0.019 mol) and then the mixture was refluxed for 
8 h. Afterward, the solution was cooled and acidified to pH 4–5 with hydrochloric acid and 
crystallized from ethanol.
General procedure for 2-chloro-N-(5-substituted-1,3,4-thiadiazol-2-yl)acetamides (3a,b). – A 
solution of 5-(substituted-amino)-1,3,4-thiadiazole-2-thiols (2a-j) (0.06 mol) in 
tetrahydrofuran was cooled in an ice bath in the presence of triethylamine (0.07 mol, 10.2 
mL), and chloroacetyl chloride (0.07 mol, 5.8 mL) was added dropwise with stirring. After 
completion of the reaction, the solvent was evaporated under reduced pressure, the 
product was washed with water, dried and recrystallized from ethanol.
General procedure for N-(5-substituted-1,3,4-thiadiazol-2-yl)-2-[(5-(substituted-amino)- 
-1,3,4-thiadiazol-2-yl)thio]acetamides (4a-y). In order to obtained the target compounds, 
compounds 3a,b (2.5 mmol) and compounds 2a-j (2.5 mmol) were reacted at room 
temperature in acetone. After completion of the reaction, the solvent was evaporated under 
reduced pressure, product was washed with water, dried and recrystallized from ethanol.
The synthesis pathway of the target compounds 4a-y is given in Scheme 1.
Physicochemical data of compounds 4a-y are given in Table I. The final compounds 
were purified and their structures were characterized by spectroscopic methods (FT-IR, 
1H NMR, 13C NMR, mass spectroscopy and elemental analyses). Spectral data of compounds 
4a-y are given in Table II.
Cytotoxicity test
MTT assay, based on the ability of metabolically active cells to convert the pale yellow 
MTT to a spectrophotometrically measured blue formazan salt, is one of the most favoured 
cytotoxicity tests (23). All of the synthesized compounds at various concentrations (1, 0.316, 
0.1, 0.0316, 0.01, 0.00316, 0.001 and 0.000316 mmol L–1) were assayed for anticancer activity in 
cancer cell lines A549 and MCF-7 (ATCC, USA) using MTT method (24, 25). Cisplatin (Sigma 
Aldrich, USA) was used as a reference drug. The cytotoxic properties of the most active 
compounds (4j, 4v and 4y) were evaluated using NIH3T3 cell line (ATCC) (23, 24).
Aromatase inhibition assay
This assay was carried out according to the kit procedure [Aromatase (CYP19A) Inhi-
bitor screening kit (fluorometric), BioVision, Boai NKY Medical Holdings Ltd., China]. The 
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compounds were dissolved in DMSO and added to the assay in at least 8 concentrations 
ranging from 1000 to 7.81 µmol L–1. Recombinant human aromatase stock was prepared by 
reconstitution with 1 mL of aromatase assay buffer. The content was mixed thoroughly by 
vortexing to obtain a homogeneous solution which was transferred to a 15-mL conical 
tube. The volume was brought to 2450 µL with aromatase assay buffer and 50 µL of NA-
DPH production system (100X) was added for a final total volume of 2.5 mL. Letrozole 
(Biovision) was used as a positive inhibition control. For solvent control, a small aliquot of 
aromatase assay buffer containing the organic solvent used to dissolve the test compounds 
was used. Reaction wells containing test compounds and corresponding no inhibitor-con-
taining controls (which may also serve as solvent controls), as well as a background control 
Compd. R1 R2 Compd. R1 R2
4a Methyl Methyl 4l Methyl Ethyl
4b Ethyl Methyl 4m Ethyl Ethyl
4c Methoxyethyl Methyl 4n Methoxyethyl Ethyl
4d Propyl Methyl 4o Propyl Ethyl
4e Isopropyl Methyl 4p Isopropyl Ethyl
4f Allyl Methyl 4r Allyl Ethyl
4g Butyl Methyl 4s Butyl Ethyl
4h Isobutyl Methyl 4t Isobutyl Ethyl
4i Cyclohexyl Methyl 4u Cyclohexyl Ethyl
4j Phenyl Methyl 4v Phenyl Ethyl
4k 4-Methylphenyl Methyl 4y 4-Methylphenyl Ethyl
Scheme 1.
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(containing no fluorogenic aromatase substrate),  were prepared. The plate was incubated 
for at least 10 min at 37 °C to allow test ligands to interact with aromatase. After incubation, 
30 µL of the aromatase substrate/NADP+ mixture was added to each well. Immediately 
(within 1 min), the fluorescence at ex/em = 488/527 nm was measured.
RESULTS AND DISCUSSION
Chemistry
The compounds 4a-y were synthesized as outlined in Scheme 1. Firstly, suitable iso-
thiocyanate and excess of hydrazine hydrate were reacted in order to obtain N-substituted 
hydrazinecarbothioamides (1a-j). Secondly, the reaction of compounds 1a-j and carbondi-
sulfide afforded 5-(substituted-amino)-1,3,4-thiadiazole-2-thiols (2a-j). The acetylation of 
thiadiazoles was performed using chloroacetyl chloride. Finally, 5-(substituted-amino)- 
-1,3,4-thiadiazole-2-thiols (2a-j) and 2-chloro-N-(5-substituted-1,3,4-thiadiazol-2-yl)acet-
amides (3a,b) were reacted in order to synthesize target compounds 4a-y.
Stretching absorption of NH groups was observed at 3285–3303 cm–1 as expected. 
Carbonyl (C=O) group gave characteristic stretching absorption in the region of 1652–1666 
cm–1. The stretching absorption at about 2916–2995 cm–1 was recorded for an aliphatic C-H 
bond. The stretching absorption belonging to 1,4-disubstituted benzene was detected at 
844–850 cm–1 for compounds 4k (N-(5-methyl-1,3,4-thiadiazol-2-yl)-2-((5-(p-tolylamino)- 
-1,3,4-thiadiazol-2-yl)thio)acetamide) and 4y (N-(5-ethyl-1,3,4-thiadiazol-2-yl)-2-((5-(p- 
-tolylamino)-1,3,4-thiadiazol-2-yl)thio)acetamide).
In the 1H NMR spectrum, the protons of the methyl (-CH3) substituents were observed 
as a singlet peak between 2.60–2.62 ppm for compounds 4a-k. The protons of the ethyl 
(-C2H5) were observed as a triplet (CH3) and quartet (-CH2) peak between 1.28–1.33 and 
2.98–2.99 ppm, resp., for compounds 4l-y. Methyl protons of compound 4y (N-(5-ethyl- 
-1,3,4-thiadiazol-2-yl)-2-((5-(p-tolylamino)-1,3,4-thiadiazol-2-yl)thio)acetamide) were found 
at 2.24 ppm as a singlet. The protons of the ethyl group in compound 4y were observed at 
1.28 ppm as a triplet and 2.98 ppm as a quartet. Moreover, methylene protons of compound 
4y had singlet peak at 4.21 ppm. Disubstituted benzene protons of compound 4y had dou-
blet peaks at 7.13 ppm (J = 8.3 Hz) and 7.43 ppm (J = 8.5 Hz). In the 13C NMR spectrum, ali-
phatic peaks belonging to substituents were observed between 11.81 ppm and 70.38 ppm. 
Aromatic carbons were identified between 116.72 and 175.17 ppm. Carbonyl carbon gave a 
peak between 166.82 and 175.17 ppm. The HRMS spectra of compounds were found to be 
in full agreement with their molecular formula.
Cytotoxicity assay
As shown in Table III, compounds 4j (N-(5-methyl-1,3,4-thiadiazol-2-yl)-2-((5-(phenyl-
amino)-1,3,4-thiadiazol-2-yl)thio)acetamide), 4v (N-(5-ethyl-1,3,4-thiadiazol-2-yl)-2-((5- 
-(phenylamino)-1,3,4-thiadiazol-2-yl)thio)acetamide) and 4y (N-(5-ethyl-1,3,4-thiadiazol-2- 
-yl)-2-((5-(p-tolylamino)-1,3,4-thiadiazol-2-yl)thio)acetamide) were identified as the most 
active compounds. These compounds were tested against noncancer NIH3T3 cells, in order 
to measure the selectivity towards cancer cells. The IC50 values of the compounds against 
cell lines are presented in Table III.
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Compound 4j and 4v, both containing phenyl moiety, showed IC50 values of 0.091 and 
0.075 mmol L–1, resp., against A549, compared to the reference drug cisplatin (0.013 mmol 
L–1). Additionally, compound 4y, containing toluene moiety, showed IC50 values of 0.084 
and 0.034 mmol L–1 against MCF-7 and A549, resp.
When the activity results are compared, it is seen that the introduction of an aromatic 
ring at the amine end of the thiadiazole increased the anticancer activity. However, the 
Table III. IC50 values of compounds 4a-y against cancer cell lines
IC50 (mmol L–1)
Compd. MCF-7 A549 Compd. MCF-7 A549
4a 0.354 ± 0.261 0.119 ± 0.071 4m 0.806 ± 0.246 0.380 ± 0.003
4b ≥ 1 0.317 ± 0.093 4n ≥ 1 0.318 ± 0.062
4c 0.593 ± 0.073 0.848 ± 0.124 4o ≥ 1 ≥ 1
4d ≥ 1 ≥ 1 4p ≥ 1 0.276 ± 0.081
4e ≥ 1 0.356 ± 0.220 4r 0.174 ± 0.065 0.223 ± 0.086
4f ≥ 1 0.230 ± 0.052 4s ≥ 1 0.694 ± 0.068
4g ≥ 1 ≥ 1 4t 0.133 ± 0.019 0.103 ± 0.008
4h ≥ 1 0.197 ± 0.153 4u ≥ 1 ≥ 1
4i ≥ 1 ≥ 1 4v 0.116 ± 0.041 0.075 ± 0.031
4j ≥ 1 0.091 ± 0.025 4y 0.084 ± 0.020 0.034 ± 0.008
4k ≥ 1 0.324 ± 0.011 Cisplatin 0.019 ± 0.009 0.013 ± 0.003
4l ≥ 1 0.326 ± 0.072
Mean ± SD, n ≥ 3.
Table IV. IC50 against NIH3T3 and SI values of compounds 4j, 4v and 4y
Compd.
IC50 (mmol L–1) 
NIH3T3
SI
4j 1.980 ± 0.066 21.76
4v 1.764 ± 0.077 15.17
4y 
Cisplatin




Mean ± SD, n = 3.
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introduction of propyl or cyclohexyl at the amine end of the thiadiazole dramatically 
reduced the anticancer activity. 
It is crucial that an anticancer agent affects the cancer cell line with having minimal 
or no effect on healthy cells. For this purpose, the cytotoxic effects of the most active 
compounds (4j, 4v and 4y) were investigated on the NIH3T3 cell line. As seen in Table III, 
IC50 of 0.084 ± 0.020 mmol L–1 of compound 4y against MCF-7 was 20-times lower than its 
IC50 of 1.790 ± 8.706 mmol L–1 against NIH3T3 cell line. The IC50 value of cisplatin was found 
to be greater than 1 mmol L–1 against NIH3T3 cell line.
The selectivity index (SI) was calculated for the effectiveness of selected compounds 
4j, 4v and 4y. The compounds with SI value > 3 are considered to exhibit selective inhibi-
tion towards cancer cells (26). Compounds 4j, 4v and 4y exhibited good selectivity since 
their SI values were in the range from 15 to 21 (Table IV).
Aromatase inhibition assay
Compound 4y which was found cytotoxic to MCF7 cancer cell line was submitted to 
aromatase inhibition assay. For this assay, a commercially available CYP19A inhibitor 
screening kit was used and letrozole was used as a positive control. Compound 4y caused 
50 % aromatase enzyme inhibition at 0.062 ± 0.004 mmol L–1, whereas the respective value 
for letrozole was calculated as 0.020 ± 0.001 mmol L–1.
CONCLUSIONS
In this study, we synthesized new N-(5-substituted-1,3,4-thiadiazol-2-yl)-2-[(5 (substituted - 
 -amino)-1,3,4-thiadiazol-2-yl)thio]acetamides (4a-y) and evaluated their anticancer potency. 
It was found that compound 4y (N-(5-ethyl-1,3,4-thiadiazol-2-yl)-2-((5-(p-tolylamino)-1,3,4-
thiadiazol-2-yl)thio)acetamide) showed promising activity against A549 and MCF-7 cell 
lines as well as promising anti-aromatase activity.
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